Found: 15
Select item for more details and to access through your institution.
The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.
- Published in:
- Vaccines, 2024, v. 12, n. 5, p. 559, doi. 10.3390/vaccines12050559
- By:
- Publication type:
- Article
Absolute quantitation of binding antibodies from clinical samples.
- Published in:
- NPJ Vaccines, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41541-023-00793-w
- By:
- Publication type:
- Article
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1215302
- By:
- Publication type:
- Article
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
- Published in:
- NPJ Vaccines, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41541-022-00564-z
- By:
- Publication type:
- Article
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
- Published in:
- PLoS ONE, 2022, v. 17, n. 10, p. 1, doi. 10.1371/journal.pone.0274906
- By:
- Publication type:
- Article
Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.
- Published in:
- Journal of Infectious Diseases, 2022, v. 226, n. 6, p. 979, doi. 10.1093/infdis/jiac142
- By:
- Publication type:
- Article
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine.
- Published in:
- Immunological Reviews, 2022, v. 310, n. 1, p. 47, doi. 10.1111/imr.13088
- By:
- Publication type:
- Article
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26117-x
- By:
- Publication type:
- Article
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.
- Published in:
- NPJ Vaccines, 2020, v. 5, n. 1, p. 1, doi. 10.1038/s41541-020-00261-9
- By:
- Publication type:
- Article
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. 1, doi. 10.3389/fimmu.2020.00669
- By:
- Publication type:
- Article
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141687
- By:
- Publication type:
- Article
A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0078679
- By:
- Publication type:
- Article
CD27 is required for generation and long-term maintenance of T cell immunity.
- Published in:
- Nature Immunology, 2000, v. 1, n. 5, p. 433, doi. 10.1038/80877
- By:
- Publication type:
- Article